• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Disease categories and therapies » Inflammatory

Inflammatory
Inflammatory RSS Feed RSS

Respiratory

An anti-inflammatory α-diazoester to treat acute lung injury

May 27, 2025
No Comments
Activation of the α7 nicotinic acetylcholine receptor may be therapeutically useful against acute lung injury by suppressing expression of pro-inflammatory genes.
Read More
Inflammatory

Arcus Biosciences describes new c-Kit inhibitors

May 23, 2025
Arcus Biosciences Inc. has identified mast/stem cell growth factor receptor Kit (KIT; c-Kit; CD117) inhibitors reported to be useful for the treatment of cancer, allergy, autoimmune, inflammatory, cardiovascular, metabolic, dermatological and respiratory disorders, among others.
Read More
Scientist, microscope and dropper
Inflammatory

Targeting RIPK1: Phenylisoxazolidine derivatives with promising anti-inflammatory activity

May 15, 2025
No Comments
Researchers at the China Pharmaceutical University have developed a series of highly active receptor-interacting protein kinase 1 (RIPK1) inhibitors with potent anti-inflammatory activity. RIPK1 is a key regulator of necroptosis, a form of programmed cell death associated with various inflammatory diseases.
Read More
3D illustration of mesenchymal stem cells

Cynata’s MSC cells show positive results across variety of delivery systems

May 13, 2025
By Tamra Sami
No Comments
The promise of mesenchymal stem cells (MSCs) to heal heart disease could be around the corner thanks to a new delivery method tested by regenerative medicine company Cynata Therapeutics Ltd.
Read More
Art concept for inflamed human tissue
Immune

Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases

May 12, 2025
No Comments
Kymera Therapeutics Inc. has announced a new oral IRF5 degrader program with potential to treat immuno-inflammatory diseases, such as lupus, Sjögren’s syndrome, rheumatoid arthritis and inflammatory bowel disease.
Read More
3D illustration of mesenchymal stem cells

Cynata’s MSC cells show positive results across variety of delivery systems

May 9, 2025
By Tamra Sami
No Comments
The promise of mesenchymal stem cells (MSCs) to heal heart disease could be around the corner thanks to a new delivery method tested by regenerative medicine company Cynata Therapeutics Ltd.
Read More
Inflammatory

Chinese scientists divulge new IL-17A inhibitors

May 7, 2025
Researchers at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have synthesized interleukin-17A (IL-17A) inhibitors reported to be useful for the treatment of inflammatory disorders.
Read More
Approved stamp

South Korea approves record number of biosimilars in 2024

May 6, 2025
By Marian (YoonJee) Chu
South Korea’s Ministry of Food and Drug Safety approved 18 biosimilar products in 2024, making it a record year for domestic biosimilar approvals since the agency’s first nod of Celltrion Inc.’s Remsima, a reference product of Remicade (infliximab), in 2012.
Read More
Kidneys

Dimerix strikes $601M Amicus deal for kidney disease drug DMX-200

May 6, 2025
By Tamra Sami
Dimerix Ltd. sealed an exclusive license agreement with Amicus Therapeutics Inc. for commercialization of its phase III kidney disease candidate, DMX-200, in a deal valued at AU$940 million (US$601.22 million).
Read More
Inflammatory

Quantx divulges new IL-17A/A and IL-17A/F inhibitors

May 5, 2025
Quantx Biosciences US Inc. has synthesized interleukin-17A/A homodimer and/or IL-17A/F heterodimer inhibitors reported to be useful for the treatment of autoimmune and inflammatory diseases.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 101 102 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • Handshake with DNA, molecules

    Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B

    BioWorld
    Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1...
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • 3D illustration of pancreatic cancer

    ASCO 2025: Verastem has positive cancer data but stock sags

    BioWorld
    New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe